NEXGEL Reports Positive Results from Proof-of-Concept Study for its Diclofenac Hydrogel Pain Treatment

Rhea-AI Summary

NEXGEL (NASDAQ: NXGL, NXGLW) announced positive outcomes from its proof-of-concept study on diclofenac hydrogel patches, aimed at treating pain including arthritis and muscle aches. The study showed that NEXGEL's patches delivered pain relief faster and were longer-acting compared to the leading treatment. These patches adhered to the skin gently for 8-12 hours. CEO Adam Levy expressed optimism about the product's potential and plans for human clinical studies, while seeking strategic partnerships for future development.

Positive

• Proof-of-concept study results indicate NEXGEL's diclofenac hydrogel patches deliver pain relief faster than competitors.
• Patches show longer-lasting effects compared to existing treatments.
• Gentle skin adhesion for 8-12 hours of effectiveness.
• Company plans to progress to human clinical studies and pursue strategic partnerships.

Negative

• None.

LANGHORNE, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today positive results from its proof-of-concept study for its diclofenac hydrogel patches. The patches are designed to treat pain indications such as arthritis, joint pain, muscle aches and more.

The study compared NEXGEL’s diclofenac hydrogel patches with the leading commercially available topical treatment. It assessed the formulations, skin retention and permeation of the products through the skin. The results revealed NEXGEL’s diclofenac hydrogel patches delivered an equivalent dose considerably faster and are longer-acting compared to the current standard-of-care, on a head-to-head basis. They also showed gentle skin adhesion for eight to 12 hours.

Diclofenac patches are a nonsteroidal anti-inflammatory drug (NSAIDs) products that are used to treat short-term pain due to minor strains, sprains and bruises. The early proof-of-concept results validate the potential effectiveness of NEXGEL’s technology in drug delivery patches.

“The early-stage data from this study showcases the efficiency of our unique hydrogel and its potential for this product to become a preferred alternative to treat pain as well its potential utility in a host of other applications,” said Adam Levy, NEXGEL CEO. “As the Company moves toward next steps of human clinical studies, we are also seeking potential strategic partners as we see this as a potential platform technology. We look forward to updating the market with our progress.”

About NEXGEL, INC.
NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. Alongside its strategic partners, NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.

Forward-Looking Statement

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs, such as "will," "should," "would," "may," and "could," are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons including the impact of the COVID-19 pandemic. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2021, including but not limited to the discussion under "Risk Factors" therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.

Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
valter@kcsa.com

Media Contacts:
Raquel Cona / Michaela Fawcett
KCSA Strategic Communications
212.896.1204 / 978.995.4683
rcona@kcsa.com / mfawcett@kcsa.com

FAQ

What were the results of NEXGEL's diclofenac hydrogel patches study?

NEXGEL's study indicated that their diclofenac hydrogel patches delivered pain relief faster and lasted longer compared to the leading topical treatment.

What is the primary use of diclofenac hydrogel patches?

Diclofenac hydrogel patches are designed to treat pain, including arthritis, joint pain, and muscle aches.

When did NEXGEL announce the study results for its hydrogel patches?

NEXGEL announced the positive results of the study on October 25, 2022.

Is NEXGEL looking for partnerships for its hydrogel patches?

Yes, NEXGEL is seeking potential strategic partners as it views its hydrogel technology as a platform for various applications.